Trial Profile
A Phase 3 Study Switching HIV-1 Infected Subjects With an Undetectable Viral Load From a HAART Regimen Dosed Twice Daily or More Frequently to a Once-Daily HAART Regimen
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Apr 2011
Price :
$35
*
At a glance
- Drugs Stavudine (Primary) ; Antiretrovirals; Efavirenz; Lamivudine
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 08 Jun 2009 New trial record.